Document is current

Article History

First Online: 25 July 2024

Competing interests

: A.P. has received research support from the National Institute of Health. A.P has received grant funding from Applied Therapeutics and Gilead Sciences; has received honoraria outside of the present study as an advisor/consultant for Tricog Health Inc, Lilly USA, Rivus, Cytokinetics, Roche Diagnostics, Axon therapies, Medtronic, Edward Lifesciences, Science37, Novo Nordisk, Bayer, Merck, Sarfez Pharmaceuticals and Emmi Solutions; and has received nonfinancial support from Pfizer and Merck. A.P. is also a consultant for Palomarin Inc. with stocks compensation. S.Z. has received research grant support; served on advisory boards for or had speaker engagements with Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cytokinetics, Eli Lilly, GSK, Medtronic, Merck, Novartis, Novo-Nordisk, Pfizer and Vifor Pharma; and serves on a clinical trial committee or as a national lead for studies sponsored by AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Pfizer and Salubris Bio.